Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer
NCT07167160Phase 2Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Cervical Cancer (CC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Started Mar 2025; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07167160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07167160.